Advertisement

Pharmacokinetic and Pharmacodynamic Factors Causing Variability in Response to Neuroleptic Drugs

  • S. G. Dahl
  • P.-A. Hals
Part of the Psychopharmacology Series book series (PSYCHOPHARM, volume 3)

Abstract

When a new psychotropic drug is introduced on the market with claims that it acts more specifically than the previous ones this has to be proven - not just in in vitro receptor binding systems and animal experiments - but also in patients. That can only be done by properly designed clinical studies.

Keywords

Schizophrenic Patient Neuroleptic Drug Plasma Drug Level Radioreceptor Assay Interpatient Variation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahtee L, Mattila MJ, Vapaatalo HI (1967) The binding of some phenothiazines to human serum in vitro. Biochem Pharmacol 16: 2432–2435PubMedCrossRefGoogle Scholar
  2. Alfredsson G, Lindberg M, Sedvall G (1982) The presence of 7-hydroxychlorpromazine in CSF of chlorpromazine-treated patients. Psychopharmacology (Berlin) 77: 376–378CrossRefGoogle Scholar
  3. Alfredsson G, Harnryd C, Wiesel F-A (1984) Effects of sulpiride and ehlorpromazine on depressive symptoms in schizophrenic patients - relationship to drug concentrations. Psychopharmacology (Berlin) 84: 237–241CrossRefGoogle Scholar
  4. Alfredsson G, Harnryd C, Wiesel FA (1985) Effects of sulpiride and ehlorpromazine on autistic and positive symptoms in schizophrenic patients - relationship to drug concentrations. Psychopharmacology (Berlin) 85: 8–13CrossRefGoogle Scholar
  5. Balant-Gorgia AE, Eisele R, Balant L, Garrone G (1984) Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. Eur Arch Psychiatr Neurol Sci 234: 1–4CrossRefGoogle Scholar
  6. Bigelow LB, Kirch DG, Braun T, Korpi ER, Wagner RL, Zalcman S, Wyatt RJ (1985) Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study. Psychopharmacol Bull 21: 66–68PubMedGoogle Scholar
  7. Bolvig Hansen L, Larsen N-E (1985) Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology (Berlin) 87: 16–19CrossRefGoogle Scholar
  8. Bolvig Hansen L, Larsen NE, Gulmann N (1982) Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology (Berlin) 78: 112–115CrossRefGoogle Scholar
  9. Brown WA, Silver MA (1985) Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate. J Clin Psychopharmacol 5: 143–147PubMedGoogle Scholar
  10. Calil HM, Avery DH, Hollister LE, Creese I, Snyder SH (1979) Serum levels of neuroleptics measured by dopamine radio receptor assay and some clinical observations. Psychiatry Res 1:39— 44Google Scholar
  11. Cohen BM, Lipinski JF, Harris PQ, Pope HG, Friedman M (1980 a) Clinical use of the radioreceptor asssay for neuroleptics. Psychiatry Res 1: 173–178Google Scholar
  12. Cohen BM, Lipinski JF, Pope HG, Harris PQ, Altesman RI (1980 b) Neuroleptic blood levels and therapeutic effect. Psychopharmacology (Berlin) 70: 191–193Google Scholar
  13. Cross AJ, Crow TJ, Owen F (1981) 3H-Flupenthixol binding in post-mortem brains of schizophrenics: Evidence for a selective increase in dopamine D2 receptors. Psychopharmacology (Berlin) 74: 122–124Google Scholar
  14. Csernansky JG, Kaplan J, Holman CA, Hollister LE (1983) Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients. Psychopharmacology (Berlin) 81: 115–118CrossRefGoogle Scholar
  15. Dahl SG (1976) Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther 19: 435–442PubMedGoogle Scholar
  16. Dahl SG (1981) Pharmacokinetic aspects of new antipsychotic drugs. Neuropharmacology 20: 1299–1302PubMedGoogle Scholar
  17. Dahl SG (1982) Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 4: 33–40PubMedCrossRefGoogle Scholar
  18. Dahl SG (1986) Plasma level monitoring of antipsychotic drugs: clinical utility. Clin Pharmacokinet 11: 36–61PubMedCrossRefGoogle Scholar
  19. Dahl SG, Hall H (1981) Binding affinity of levomepromazine and two of its major metabolites to central dopamine and adrenergic receptors in the rat. Psychopharmacology (Berlin) 74: 101–104CrossRefGoogle Scholar
  20. Dahl SG, Strandjord RE (1977) Pharmacokinetics of ehlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 437–448PubMedGoogle Scholar
  21. Davis JM, Ericksen SE, Hurt S, Chang SS, Javaid JI, Dekirmenjian H, Casper R (1985) Haloperidol plasma levels and clinical response: basic concepts and clinical data. Psychopharmacol Bull 21: 48–51PubMedGoogle Scholar
  22. Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM (1981) Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology (Berlin) 73: 205–210CrossRefGoogle Scholar
  23. Freedberg KA, Innis RB, Creese I, Snyder SH (1979) Antipsychotic drugs: differential plasma protein binding and therapeutic activity. Life Sci 24: 2467–2474PubMedCrossRefGoogle Scholar
  24. Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis ML (1984) Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol 4: 133–137PubMedCrossRefGoogle Scholar
  25. Hals PA, Hall H, Dahl SG (1986) Phenothiazine drug metabolites: Dopamine D2 receptor, α1 and α2-adrenoceptor binding. Eur J Pharmacol 125: 373–381PubMedCrossRefGoogle Scholar
  26. Hulka BS, Cassel JC, Kupper LL (1976) Disparities between medications prescribed and consumed among chronic disease patients. In: Lasagna L (ed) Patient Compliance. Futura Mount Kisco, New York, pp 123–152Google Scholar
  27. Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism, vol 9. Taylor and Francis, London, pp 111–174Google Scholar
  28. Kirch DG, Bigelow LB, Wyatt RJ (1985) The interpretation of plasma haloperidol concentrations. Arch Gen Psychiatry 42: 838–836PubMedGoogle Scholar
  29. Krieglstein J, Lier F, Michaelis J (1972) Albumin binding and hydrophobic character of promazine and chlorpromazine metabolites. Arch Pharmacol 272: 121–130CrossRefGoogle Scholar
  30. Kucharski LT, Alexander P, Tune L, Coyle J (1984) Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients. Psychopharmacology (Berlin) 82: 194–198CrossRefGoogle Scholar
  31. Larsson M, Axelsson R, Forsman A (1984) On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate. Curr Therapeutic Res 36: 1071–1088Google Scholar
  32. Lindenmayer JP, Smith D, Katz I (1984) Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients. J Clin Psychiatry 45: 117–119PubMedGoogle Scholar
  33. Linkowski P, Houbain P, Von Frenckell R, Mendlewicz J (1984) Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatr Neurol Sci 234: 231–236CrossRefGoogle Scholar
  34. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1983) Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology (Berlin) 81: 354–356CrossRefGoogle Scholar
  35. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984 a) Therapeutic blood levels of fluphenazine: Plasma or RBC determinations? Psychopharmacol Bull 20: 168–170Google Scholar
  36. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984 b) Fluphenazine plasma levels and clinical response. J Clin Psychiatry 45: 370–373Google Scholar
  37. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984 c) Clinical relevance of thiothixene plasma levels. J Clin Psychopharmacol 4: 155–157Google Scholar
  38. Mavroidis ML; Garver DL, Kanter DR, Hirschowitz J (1985) Plasma haloperidol levels and clinical response: confounding variables. Psychopharmacol Bull 21: 62–65PubMedGoogle Scholar
  39. Meitzer HY, Busch DA, Fang VS (1983) Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 9: 271–283CrossRefGoogle Scholar
  40. Newman DC, Epperly M, Sangarasivam S, Maruta T, Homburger HA (1984) Neuroleptic levels in serum: clinical usefulness in schizophrenic patients. Clin Res 32:741 AGoogle Scholar
  41. Richelson E, Nelson A (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103: 197–204PubMedCrossRefGoogle Scholar
  42. Potkin SG, Shen Y, Zhou D, Pardes H, Shu L, Phelps B, Poland R (1985) Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacol Bull 21: 59–61PubMedGoogle Scholar
  43. Silverstone T, Cookson J, Ball R, Chin CN, Jacobs D, Lader S, Gould S (1984) The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. J Psychiatry Res 18: 255–268CrossRefGoogle Scholar
  44. Smith RC, Vroulis G, Misra CH, Schoolar J, De John C, Korivi P, Leelavahti DE, Arzu D (1980) Receptor techniques in the study of plasma levels of neuroleptics and antidepressant drugs. Commun Psychopharmacol 4: 451–465PubMedGoogle Scholar
  45. Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, Ho BT, De John C (1984 a) Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays. Arch Gen Psychiatry 41: 1044–1049Google Scholar
  46. Smith RC, Baumgartner R, Ravichandran GK, Shvartsburd A, Schoolar JC, Allen P, Johnson R (1984 b) Plasma and red cell levels of thioridazine and clinical response in schizophrenia. Psychiatry Res 12: 287–296Google Scholar
  47. Smith RC, Baumgartner R, Burd A, Ravichandran GK, Mauldin M (1985) Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assays. Psychopharmacol Bull 21: 52–58PubMedGoogle Scholar
  48. Tang SW, Glaister J, Davidson L, Toth R, Jeffries JJ, Seeman P (1984) Total and free plasma neuroleptic levels in schizophrenic patients. Psychiatry Res 13: 285–293PubMedCrossRefGoogle Scholar
  49. Tune LE, Creese I, De Paulo JR, Slavney PR, Coyle JT, Snyder SH (1980) Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. Am J Psychiatry 137: 187–190PubMedGoogle Scholar
  50. Tune LE, Creese I, De Paulo JR, Slavney PR, Snyder SH (1981) Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenia. J Nerv Ment Dis 169: 60–63PubMedCrossRefGoogle Scholar
  51. Van Putten T, May PRA, Jenden DJ (1981) Does a plasma level of chlorpromazine help? Psychol Med 11: 729–734PubMedCrossRefGoogle Scholar
  52. Van Putten T, May PRA, Marder SR, Wilkins JN, Rosenberg BJ (1983) Plasma levels of thiothixene by radioreceptor assay: clinical usefulness. Psychopharmacology (Berlin) 79: 40–44CrossRefGoogle Scholar
  53. Van Putten T, Marder SR, May PRA, Poland RE, O’Brien RP (1985 a) Plasma levels, haloperidol and clinical response. Psychopharmacol Bull 21: 69–72Google Scholar
  54. Van Putten T, Marder SR, Mintz (1985 b) Plasma haloperidol levels: clinical response and fancy mathematics. Arch Gen Psychiatry 42: 835Google Scholar
  55. Wode-Helgodt B, Alfredsson G (1981) Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses. Psychopharmacology (Berlin) 73: 55–62CrossRefGoogle Scholar
  56. Wode-Helgodt B, Borg S, Fyrö B, Sedvall G (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 58: 149–173PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • S. G. Dahl
    • 1
  • P.-A. Hals
    • 1
  1. 1.Department of Pharmacology, Institute of Medical BiologyUniversity of TromsöTromsöNorway

Personalised recommendations